Topaz Pharmaceuticals Inc

Topaz Pharmaceuticals Inc is a technology company.

Active

Updated: Mar 22, 2026 ·

About

Topaz Pharmaceuticals Inc. developed and commercialized specialized pharmaceutical products for pediatric patients. The company focused on distinct health needs in children, offering treatments for conditions like head lice, notably with its prescription product Sklice, and acne. Their approach also included vaccines and medications for various infections, emphasizing child-appropriate formulations.

Founded in 2005 by Nicholas Spring and Donald P. Beeman, former Merck & Co. Inc. executives, Topaz Pharmaceuticals emerged from the insight that optimizing an existing drug could effectively treat head lice. This strategic focus on adapting pharmaceutical solutions for specific unmet pediatric needs underpinned their strategy.

Topaz Pharmaceuticals Inc. served the pediatric healthcare market, providing solutions to families, pediatricians, and healthcare professionals. The company's mission was to enhance children's health and well-being by delivering essential medicines specifically designed for this vulnerable patient group, striving for better therapeutic outcomes.

Recent News & Mentions

Dec 1, 2007FundingTopaz Pharmaceuticals Inc - Series A

Financial History

Topaz Pharmaceuticals Inc has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series A in December 2007.

Total Raised

$20.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Dec 1, 2007	$20.0M Series A		Genoa Ventures

Financial History

Topaz Pharmaceuticals Inc has raised $20.0M across 1 funding round.

Total Raised

$20.0M

Valuation

N/A

Deep Dive

Topaz Pharmaceuticals Inc. is a specialty pharmaceutical company (not a general “technology company”) focused on developing pediatric and topical prescription treatments; it has been known for Sklice (a topical treatment for head lice) and was acquired by Sanofi/Pasteur-related interests according to public profiles[1][4].[1]

High‑Level Overview

concise summary: Topaz Pharmaceuticals is a small specialty pharma company that positioned itself around pediatric infectious‑disease and topical therapies (not a broad tech firm); its public profiles list Sklice (a topical head‑lice product) as a lead asset and show the company was later acquired by Sanofi/Pasteur interests[1][4].[1]
For an investment firm (not applicable): Topaz is a portfolio/operating company, not an investment firm; the investment‑firm headings therefore do not apply.- For a portfolio company (applicable):
What product it builds: a topical prescription product for head lice (Sklice) and pediatric therapeutics pipeline assets as reported in company summaries[1][5].[1][5]
Who it serves: pediatric patients and caregivers seeking kid‑friendly, topical treatments for common pediatric conditions such as head lice[4][5].[4][5]
What problem it solves: provides safer, user‑friendly, topical therapeutic options for pediatric infectious conditions (reducing treatment burden for children and families)[5].[5]
Growth momentum: early‑stage/startup profiles show initial investment activity (F‑Prime listed an initial investment in 2007) and an eventual acquisition by Sanofi/Pasteur interests, indicating exit/validation rather than ongoing independent scale-up in public records[1].[1]

Origin Story

Founding year & early stage: public investor pages indicate Topaz received early investment around 2007 and was structured as a pediatric specialty pharma startup pursuing kid‑friendly medicines[1][5].[1][5]
Founders and background / how idea emerged: available summaries describe Topaz as founded to address unmet pediatric needs and to develop novel kid‑friendly topical prescription products, but I did not find named founders or a detailed narrative in the cited profiles; company database summaries and startup program listings corroborate the pediatric focus and early‑stage framing[4][5].[4][5]
Early traction / pivotal moments: initial venture backing (listed by F‑Prime) and later acquisition by Sanofi/Pasteur are the main documented milestones in public profiles, suggesting the company achieved sufficient clinical/ commercial progress to attract an acquirer[1][3].[1][3]

Core Differentiators

Product focus: specialization in pediatric and topical prescription therapies (narrow therapeutic niche rather than broad drug discovery)[1][5].[1][5]
Kid‑friendly product design: emphasis on formulations and delivery appropriate for children, a recognized unmet need in pediatric therapeutics programs cited in startup descriptions[4][5].[4][5]
Exit/validation: acquisition by a major pharmaceutical group (Sanofi/Pasteur reported in investor/company pages) signals commercial/strategic validation relative to peers[1].[1]
Small‑company agility: as a startup, Topaz could prioritize specific pediatric indications and rapid formulation development compared with larger pharma R&D processes (inference based on typical startup vs. big‑pharma positioning; not explicitly detailed in the cited pages).[5]

Role in the Broader Tech/Pharma Landscape

Trend they are riding: focused pediatric therapeutics and specialty topical formulations—areas that attract attention because pediatric drug development is under‑served and formulation/administration are key differentiators for children[5].[5]
Timing: regulators and payers have grown more receptive to pediatric‑focused development pathways and incentives, improving prospects for niche pediatric drug companies (general industry context; Topaz’s acquisition is consistent with larger pharma sourcing specialty assets)[1][3].[1][3]
Market forces: unmet pediatric needs, valuation of niche products by larger pharma for portfolio diversification, and consolidation in specialty therapeutics favor startups that prove clinical efficacy and tolerability in targeted indications[1][3].[1][3]
Influence: as a small specialty developer that reached acquisition, Topaz exemplifies the pipeline‑to‑exit path that supplies larger pharmas with niche, de‑risked assets—supporting an ecosystem where small teams focus on formulation and clinical work and larger players handle commercialization[1][3].[1][3]

Quick Take & Future Outlook

What’s next (historical/forward view): publicly available records indicate Topaz ultimately became part of Sanofi/Pasteur’s portfolio—future development and commercialization of its assets likely proceeded under the acquiring organization rather than under Topaz as an independent public company[1].[1]
Trends that will shape trajectory: continued interest in pediatric‑appropriate formulations, regulatory incentives for pediatric development, and M&A by large pharma looking for specialty assets will determine how similar small specialty pharma firms evolve[5][1].[5][1]
How influence may evolve: Topaz’s path—from niche pediatric focus to acquisition—reinforces a repeatable model for small specialty biopharma teams: validate a targeted clinical product and partner or sell to scale commercialization; this model will remain influential where large pharma needs pipeline replenishment[1][3].[1][3]

Notes, caveats and sources

Public profiles used here are investor/company listings and startup directories; they confirm Topaz’s specialty pediatric/topical focus and acquisition but do not provide a comprehensive corporate history or named founders in the cited pages[1][4][5].[1][4][5]
If you want a deeper corporate timeline, named founders, clinical data, patent filings or exact acquisition terms, I can pull regulatory filings, press releases, or clinical‑trial/patent databases next—tell me which detail you want and I’ll fetch and cite those sources.

Sources

Frequently Asked Questions

How much funding has Topaz Pharmaceuticals Inc raised?

Topaz Pharmaceuticals Inc has raised $20.0M in total across 1 funding round.

Who are Topaz Pharmaceuticals Inc's investors?

Topaz Pharmaceuticals Inc's investors include Genoa Ventures.